Not Signed In - Somaxon Pharmaceuticals Provides Update On SILENOR(TM) Development Program For The Treatment Of Insomnia
Thu, 20 Jul 2006 06:00 AM EST
... Somaxon Pharmaceuticals,Inc. (Nasdaq: SOMX) today is providing information on its developmentprogram for SILENOR(TM) (doxepin HCl), its lead drug candidate currently inPhase 3 clinical trials for the treatment of insomnia. The company isupdating information regarding the preclinical testing program forSILENOR(TM) recently requested by the U.S. Food and Drug Administration(FDA). [click link for full article] ...
Related Topics
- Insomnia
- Child Development
- Community Development
- Fetal Development
- Teen Development
- Infant and Toddler Development
- Substance Abuse
- Development of antibodies (inhibitors) to fibrinogen with treatment
- Intervention
- Vaccine Development
- Adolescents/Adolescence
- Hypersomnia
- Treatment
- Primary Insomnia
- Perimenopause
- Treatments
- Newborn Care
- Housing
- Chemical Dependency
- Telemedicine
email this page
print this page
bookmark this page
feedback on this page
